S
Stan Chetcuti
Researcher at University of Michigan
Publications - 10
Citations - 3642
Stan Chetcuti is an academic researcher from University of Michigan. The author has contributed to research in topics: Valve replacement & Aortic valve replacement. The author has an hindex of 9, co-authored 10 publications receiving 3170 citations. Previous affiliations of Stan Chetcuti include Mount Sinai Health System.
Papers
More filters
Journal ArticleDOI
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis
David H. Adams,Jeffrey J. Popma,Michael J. Reardon,Steven J. Yakubov,Joseph S. Coselli,G. Michael Deeb,Thomas G. Gleason,Maurice Buchbinder,James B. Hermiller,Neal S. Kleiman,Stan Chetcuti,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,John V. Conte,Brijeshwar Maini,Mubashir Mumtaz,Sharla Chenoweth,Jae K. Oh +23 more
TL;DR: In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aorti-valve bioprosthesis was associated with a significantly higher rate of survival at 1 year than surgical aorticsvalve replacement.
Journal ArticleDOI
2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement
Michael J. Reardon,David H. Adams,Neal S. Kleiman,Steven J. Yakubov,Joseph S. Coselli,G. Michael Deeb,Thomas G. Gleason,Joon S. Lee,James B. Hermiller,Stan Chetcuti,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,Brijeshwar Maini,Mubashir Mumtaz,John V. Conte,Jon R. Resar,Vicken Aharonian,Thomas A. Pfeffer,Jae K. Oh,Hongyan Qiao,Jeffrey J. Popma +26 more
TL;DR: In patients with severe aortic stenosis who are at increased surgical risk, the higher rate of survival with a self-expanding TAVR compared with surgery was sustained at 2 years.
Journal ArticleDOI
3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement
G. Michael Deeb,Michael J. Reardon,Stan Chetcuti,Himanshu J. Patel,P. Michael Grossman,Steven J. Yakubov,Neal S. Kleiman,Joseph S. Coselli,Thomas G. Gleason,Joon S. Lee,James B. Hermiller,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,Brijeshwar Maini,Mubashir Mumtaz,John V. Conte,Jon R. Resar,Vicken Aharonian,Thomas A. Pfeffer,Jae K. Oh,Hongyan Qiao,David H. Adams,Jeffrey J. Popma,CoreValve U.S. Pivotal High Risk Trial Clinical Investigators +29 more
TL;DR: Patients with severe aortic stenosis at increased risk for surgery had improved 3-year clinical outcomes after TAVR compared with surgery, and aorti valve hemodynamics were more favorable in TAVr patients without differences in structural valve deterioration.
Journal ArticleDOI
5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients
Thomas G. Gleason,Michael J. Reardon,Jeffrey J. Popma,G. Michael Deeb,Steven J. Yakubov,Joon S. Lee,Neal S. Kleiman,Stan Chetcuti,James B. Hermiller,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,John V. Conte,Mubashir Mumtaz,Jae K. Oh,Jian Huang,David H. Adams,CoreValve U.S. Pivotal High Risk Trial Clinical Investigators +22 more
TL;DR: This study shows similar mid-term survival and stroke rates in high-risk patients following TAVR or SAVR, and suggests that valve reinterventions were uncommon.
Journal ArticleDOI
Early Clinical Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Who Are Suboptimal for Surgery: Results of the Evolut R U.S. Study
Jeffrey J. Popma,Michael J. Reardon,Kamal R. Khabbaz,J. Kevin Harrison,G. Chad Hughes,Susheel Kodali,Isaac George,G. Michael Deeb,Stan Chetcuti,Robert Kipperman,John V. Brown,Hongyan Qiao,James Slater,Mathew R. Williams +13 more
TL;DR: It is concluded that this novel self-expandable TAV bioprosthesis is safe and effective for the treatment of patients with severe aortic stenosis who are suboptimal for surgery.